In 516 patients with standard-risk newly diagnosed multiple myeloma not having up-front transplant, continuous lenalidomide maintenance did not improve overall survival vs 2 years (7-year OS 68.6% vs 69.0%; P=0.93), with more grade ≥3 nonhaematologic events (48.2% vs 31.5%).
RCTn = 516
Kumar et al. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma